Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 14/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28518407 | 1.00 | PTPN11 (0.52) | PTPN11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL28610638 | 0.92 | PTPN11 (0.49) | PTPN11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL31058110 | 0.90 | HDAC3 (0.46) | PTPN11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL23063936 | 0.88 | PTPN11 (0.56) | PTPN11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL28624033 | 0.87 | PTPN11 (0.52) | PTPN11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL28614826 | 0.87 | PTPN11 (0.44) | PTPN11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30677193 | 0.86 | PTPN11 (0.48) | PTPN11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30809714 | 0.86 | PTPN11 (0.48) | PTPN11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL23064015 | 0.86 | PTPN11 (0.48) | PTPN11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL21115213 | 0.86 | HDAC3 (0.57) | PTPN11HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | NAVIRE PHARMA, INC. (US) | 2024-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | PTPN11, PTPRJ, PTPRCAP | PTPN11 1/4885HDAC3 1462/4885HDAC4 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.